» Articles » PMID: 11035908

Osteoporosis and Osteoporotic Fractures in Men: a Clinical Perspective

Overview
Specialty Endocrinology
Date 2000 Oct 19
PMID 11035908
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

The lifetime risk of any fracture of the hip, spine or distal forearm in men aged 50 years has been estimated to be 13%, compared with 40% in women. Although the overall incidence of osteoporosis is less in men than in women, the disease still represents an important public health problem. In particular, hip fractures are associated with substantial mortality and morbidity, even more so than in women. In male patients presenting with osteoporotic fractures, major causes of skeletal fragility, such as hypogonadism, glucocorticoid excess, primary hyperparathyroidism and alcohol abuse, can often be identified. In as many as 50% of osteoporotic men, however, no aetiology can be found: these men suffer from a syndrome commonly referred to as idiopathic osteoporosis, which is presumably related to some type of osteoblast dysfunction. Recent evidence indicates that the loss of skeletal integrity in ageing men may be partially related to endocrine deficiencies, including vitamin D, androgen and/or oestrogen deficiency. While the consequences of vitamin D or oestrogen deficiency in women have been well established, the skeletal impact of these (partial) age-related deficiencies in men remains to be clarified. Osteoporosis in elderly men is a multifactorial disease, as it is in women. The prevention of osteoporosis should therefore focus not only on increasing the bone strength, but also on decreasing the risk of falls. However, the prevention and therapy of osteoporotic disorders in men are virtually unexplored. To date, the use of specific osteoporotic drugs in osteoporotic men is still based on reasonable but untested assumptions.

Citing Articles

Osteoporosis and dermatoporosis: a review on the role of vitamin D.

Romano F, Serpico D, Cantelli M, Di Sarno A, Dalia C, Arianna R Front Endocrinol (Lausanne). 2023; 14:1231580.

PMID: 37693364 PMC: 10484397. DOI: 10.3389/fendo.2023.1231580.


CoQ10 suppression of oxidative stress and cell senescence increases bone mass in orchiectomized mice.

Wu X, Liang S, Zhu X, Wu X, Dong Z Am J Transl Res. 2020; 12(8):4314-4325.

PMID: 32913507 PMC: 7476121.


Analysis of the Relationship between the Levels of Androgens and Biochemical Bone Markers in Men Aged 60-75 Years.

Ryl A, Szylinska A, Jurewicz A, Bohatyrewicz A, Miazgowski T, Rotter I Int J Environ Res Public Health. 2019; 17(1).

PMID: 31877849 PMC: 6982106. DOI: 10.3390/ijerph17010106.


The evidence for efficacy of osteoporosis treatment in men with primary osteoporosis: a systematic review and meta-analysis of antiresorptive and anabolic treatment in men.

Schwarz P, Jorgensen N, Mosekilde L, Vestergaard P J Osteoporos. 2011; 2011:259818.

PMID: 21776371 PMC: 3138068. DOI: 10.4061/2011/259818.


Osteoporosis in men.

Khosla S, Amin S, Orwoll E Endocr Rev. 2008; 29(4):441-64.

PMID: 18451258 PMC: 2528848. DOI: 10.1210/er.2008-0002.